P. Joly
YOU?
Author Swipe
View article: Bullous Pemphigoid Outcome Measurement: A Scoping Review of Outcome Heterogeneity and Trends in Clinical Research of Treatments
Bullous Pemphigoid Outcome Measurement: A Scoping Review of Outcome Heterogeneity and Trends in Clinical Research of Treatments Open
Background Bullous pemphigoid (BP) is the most common autoimmune bullous disease, characterized by development of tense blisters and pruritus. BP is a chronic disease, requiring long-term treatment often associated with serious side effect…
View article: Sun Exposure Behaviors of Patients With Moderate‐to‐Severe Psoriasis: Results From the French PSOBIOTEQ Cohort
Sun Exposure Behaviors of Patients With Moderate‐to‐Severe Psoriasis: Results From the French PSOBIOTEQ Cohort Open
Background Tanning addiction is a behavioral addiction characterized by an irrepressible desire for sun or ultraviolet light exposure. It is thought to affect 10% to 25% of the population. Objectives This study aimed to estimate the preval…
View article: Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions
Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions Open
Background Pemphigus is an autoimmune bullous disease (AIBD) and has two main subtypes, pemphigus vulgaris (PV) and pemphigus foliaceus (PF). For adequate interpretation and comparison of clinical studies in pemphigus, it is essential to h…
View article: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study Open
[This corrects the article DOI: 10.1016/j.eclinm.2024.102679.].
View article: Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review) Open
Bullous pemphigoid (BP) is an autoimmune blistering disease that most often affects elderly individuals and has a significant negative impact on quality of life. The disease is characterized primarily by autoantibodies to hemidesmosomal pr…
View article: Bullous pemphigoid burden of disease, management and unmet therapeutic needs
Bullous pemphigoid burden of disease, management and unmet therapeutic needs Open
Bullous pemphigoid (BP) is an autoimmune blistering disease that can have a profound negative impact on quality of life. BP most often affects the elderly, a population with a high medical burden and special safety concerns. In this review…
View article: Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program Open
A video abstract is now available for this publication, which can be viewed online. The video abstract can also be accessed on the article’s Figshare page here: https://doi.org/10.6084/m9.figshare.24749436 and in the parent article as Supp…
View article: Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study Open
Overall, rilzabrutinib was well-tolerated, with similar adverse events reported in both groups. Using minimal CS dose ≤10 mg/d and excluding remote observations, the primary efficacy endpoint was not met. However, results from a prespecifi…
View article: S2k guidelines on diagnosis and treatment of linear <scp>IgA</scp> dermatosis initiated by the European Academy of Dermatology and Venereology
S2k guidelines on diagnosis and treatment of linear <span>IgA</span> dermatosis initiated by the European Academy of Dermatology and Venereology Open
Introduction Linear IgA dermatosis (LAD) is a rare subepidermal autoimmune bullous disease (AIBD) defined by predominant or exclusive immune deposits of immunoglobulin A at the basement membrane zone of skin or mucous membranes. This disor…
View article: Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy Open
Importance The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received r…
View article: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program Open
Article full text The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer…
View article: Overview of Clinical Trials With Efgartigimod in Autoimmune Blistering Diseases: Pemphigus Vulgaris and Pemphigus Foliaceus (ADDRESS and ADDRESS+) and Bullous Pemphigoid (BALLAD and BALLAD+)
Overview of Clinical Trials With Efgartigimod in Autoimmune Blistering Diseases: Pemphigus Vulgaris and Pemphigus Foliaceus (ADDRESS and ADDRESS+) and Bullous Pemphigoid (BALLAD and BALLAD+) Open
Introduction & Objectives: Efgartigimod is an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor (FcRn), thereby reducing levels of circulating IgG including pathogenic IgG autoantibodies. Pemphigus vulgaris (PV)…
View article: Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program Open
AA is an autoimmune disease with an underlying immunoinflammatory pathogenesis characterized by nonscarring hair loss ranging from small bald patches to complete loss of scalp, face, and body hair 1 • In the ALLEGRO phase 2b/3 study, ritle…
View article: Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)
Corrigendum: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (<span>EADV</span>) Open
Correction for the following article: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)
View article: Rituximab tunes desmoglein-3-specific follicular T cells in patients with pemphigus vulgaris
Rituximab tunes desmoglein-3-specific follicular T cells in patients with pemphigus vulgaris Open
Background : Pemphigus vulgaris (PV) is characterized by pathogenic auto-antibodies targeting interkeratinocytes desmoglein (Dsg) 1 and 3, and by the HLA-DRB1-0402 predisposition allele. Treatment using rituximab (RTX) combined with short-…
View article: S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)
S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (<span>EADV</span>) Open
Background Paraneoplastic pemphigus (PNP), also called paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare autoimmune disease with mucocutaneous and multi‐organ involvement. PNP/PAMS is typically associated with lymphoprolifera…
View article: Editorial: Autoimmune blistering diseases, volume II
Editorial: Autoimmune blistering diseases, volume II Open
International audience